Celebrex, Mobic Not Worth Extra Expense, Journal Analysis Finds
This article was originally published in The Pink Sheet Daily
Payors and consumers overspent nearly $6 bil. over three years by choosing celecoxib and meloxicam over traditional, less-expensive therapies, according to Journal of Managed Care Pharmacy.
You may also be interested in...
British Medical Journal researchers were concerned to find increased risk for rofecoxib since lower GI risk “was one of the main justifications for use.”
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13
Merger will create the leading generic injectable pharmaceutical company in the world.